

# Sussex Research

## The rise of companies from emerging markets in global health governance: opportunities and challenges

Anne Roemer-Mahler

### Publication date

01-12-2014

### Licence

This work is made available under the **Copyright not evaluated** licence and should only be used in accordance with that licence. For more information on the specific terms, consult the repository record for this item.

### Document Version

Accepted version

### Citation for this work (American Psychological Association 7th edition)

Roemer-Mahler, A. (2014). *The rise of companies from emerging markets in global health governance: opportunities and challenges* (Version 1). University of Sussex. <https://hdl.handle.net/10779/uos.23415713.v1>

### Published in

Review of International Studies

### Link to external publisher version

<https://doi.org/10.1017/S0260210514000345>

### Copyright and reuse:

This work was downloaded from Sussex Research Open (SRO). This document is made available in line with publisher policy and may differ from the published version. Please cite the published version where possible. Copyright and all moral rights to the version of the paper presented here belong to the individual author(s) and/or other copyright owners unless otherwise stated. For more information on this work, SRO or to report an issue, you can contact the repository administrators at [sro@sussex.ac.uk](mailto:sro@sussex.ac.uk). Discover more of the University's research at <https://sussex.figshare.com/>

**Table 2: Developing countries biopharmaceutical companies' involvement in global health partnerships**

		Funding/Procurement Partnerships			Product Development Partnerships									Capacity Building Partnership
		GFATM	GDF	GAVI	IDRI	MMV	Aeras	DNDi	Sabin	PATH/ OWH	TB Alliance	IAVI	IAVI Innovation Fund	WHO GAP
Country	Firm													
Brazil	Bio-Manguinhos			X					X					
	Instituto Butantan								X					X
	Orange Life				X									
China	Beijing Tiantan									X				
	Cansino						X							
	Chengdu Institute									X				
	China Gateway									X				
	Chongqing Holley					X								
	CNBG						X							
	Ease Medtrend				X									
	Frontier Biosciences								X					
	Guilin Pharma	X				X								
	Holley Cotec	X												
	Kunming Pharma					X								
	Shanghai ChemPartner									X				
	Shijiazhuang	X												
	Wuhan Institute									X				

		GFATM	GDF	GAVI	IDRI	MMV	Aeras	DNDi	Sabin	PATH/ OWH	TB Alliance	IAVI	IAVI Innovation Fund	WHO GAP
<b>Colombia</b>	Humanx							X						
	Laboratorios Legrand S.A.	X												
<b>Egypt</b>	Vacsera													X
<b>India</b>	Ajanta	X												
	Advinus							X						
	Aurobindo	X												
	Bharat	X								X				
	Biological E.	X		X										
	Cadila	X	X		X									
	Cipla	X	X			X		X						
	Emcure	X												
	Gennova				X					X				
	Gland	X								X				
	Hetero	X												
	Intas	X												
	IPCA Labs.	X				X								
	Lupin	X	X											
	MacLeods	X	X											
	Maneesh	X												
	Matrix	X												
	Medopharm	X												
	Micro Labs	X	X											
	Naxpar	X												
	Ranbaxy	X				X								
	Serum Institute	X		X			X			X				X
	Span Diagnostics				X									
	Strand Life												X	
	Strides	X	X											
	Syngene									X				

[illegible]